Articles tagged with Influenza Viruses
The La Jolla Institute completed a first-of-its-kind study analyzing all published data worldwide on influenza A virus antibody and T cell epitopes. The study provides critical information for developing vaccines and therapies against both seasonal and pandemic influenza strains.
Scientists at NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases have successfully imaged the influenza virus using electron tomography, revealing five distinct types of particles. This breakthrough provides insight into the virus's structure and potential targets for vaccine development.
A new study analyzed 413 complete influenza genomes from New York State, showing genetically distinct viral strains circulate across the state and exchange genes through reassortment. Adaptive evolution in influenza virus is strongly affected by chance events, making predicting future patterns more difficult.
Researchers found that mice with a genetic predisposition to severe flu symptoms mount an enhanced immune response in the lungs compared to those with milder disease. The study aims to identify genes controlling inflammation variation during influenza infection and may help determine who would benefit most from limited vaccine supply.
A new experimental vaccine has shown significant protective effects against multiple H5N1 strains in lab animals. The two-dose vaccination schedule induced higher levels of antibodies that were cross-reactive to various viruses, suggesting a potential solution for stockpiling vaccines during pandemics.
The International Society for Influenza and other Respiratory Diseases has launched a new journal, Influenza and Other Respiratory Viruses, with renowned influenza expert Alan Hampson at the helm. The journal aims to bring together international knowledge and expertise in combating the global threat of an influenza pandemic.
The H5N1 virus poses a significant threat, prompting researchers to revisit studies of influenza A viruses. The immune system response to H5N1 can be catastrophic, with a 'cytokine storm' causing rapid death. Understanding the battle between the immune system and influenza A viruses holds promise for better therapies and vaccines.
A CDC study found alarmingly high adamantane resistance rates of 92% among influenza A viruses isolated from patients in the US. Rapid surveillance is critical to prevent resistant viruses from spreading, especially in vulnerable populations like nursing homes.
Researchers at UW-Madison have discovered a systematic mechanism for the influenza virus to package its genetic materials, enabling the development of new antiviral drugs and more efficient vaccine production. This finding has significant implications for addressing avian influenza pandemics.
Researchers found that two classes of antivirals prevented flu symptoms but not infection, and did not stop virus shedding. Dr. Tom Jefferson advises against using these drugs for seasonal influenza control, citing low effectiveness and potential adverse effects.
Leading NIAID researchers explore the complex relationship between influenza viruses and the human immune system. They explain how antigenic drift and shift impact vaccine development, highlighting potential vulnerabilities to flu pandemics.
A study on H5N1 influenza virus infection in cats reveals systemic disease with widespread viral spread to various organ systems, including respiratory and digestive tracts. This finding has significant implications for understanding the mechanisms of avian influenza transmission to humans.
A new study has tracked the evolution of the H3N2 influenza virus in New York over five flu seasons, revealing at least three distinct subpopulations of the virus. The research demonstrates the potential for genomics to inform vaccine development and improve public health by understanding the dynamics of flu virus evolution.
Researchers sequenced over 200 human flu strains, revealing a surprisingly large degree of genetic diversity and dynamic evolution. The study provides insights into why the 2003-04 flu vaccine provided partial protection against that season's flu.
Researchers tested oseltamivir on mice infected with H5N1 virus, finding that higher doses for longer periods improved survival rates. The study suggests that antiviral drugs like oseltamivir may be effective in preventing and treating avian flu.
The NIAID genome sequencing project aims to reveal the genetic blueprints of thousands of human and avian influenza viruses, providing valuable data for researchers studying the virus's evolution and potential targets for new vaccines. The publicly available sequence information will help epidemiologists and other researchers improve t...
A Japanese study found that neuraminidase inhibitor oseltamivir-resistant viruses emerged more frequently in children treated for influenza, posing a potential risk of transmission. The research also highlights the need for further investigation into the mechanisms of resistance to prevent and treat future pandemics.
Researchers created a map of the influenza A (H3N2) virus's antigenic and genetic evolution from 1968 to 2003, revealing 11 closely related virus clusters. The approach will aid in monitoring antigenic differences among vaccine strains and predicting infection success of emerging viruses.
Sir John Skehel's 30-year research on the influenza virus has led to a deeper understanding of how it infects cells and evolves to evade the immune system. His discovery has helped develop antiviral drugs targeting viral surface proteins, saving millions from global flu outbreaks.
The study found that subtle alterations in the influenza virus's infectivity led to its deadly spread. The researchers determined that a key contributor was the hemagglutinin protein, which allowed the virus to bind to human receptors in an antigenically favorable way.
The researchers solved the structure of the hemagglutinin protein, a crucial component in understanding the 1918 flu outbreak. The study reveals that the virus likely originated from birds and its unique surface proteins made it particularly deadly to young adults.
Researchers found that post-exposure oseltamivir prophylaxis significantly reduced virus transmission and illness in households. The strategy was more effective than treating the ill household member only, with a 63% protective efficacy rate.
A nasal spray flu vaccine has been shown to be effective in preventing acute respiratory illness in all age groups. The vaccine was found to be particularly effective in preventing natural influenza A (H1N1) infection among children aged 5-9 years during the 2000-2001 epidemic.
The Flu Chip will enable doctors to swiftly diagnose respiratory illness, including influenza A, B and C, SARS, and other viruses. The technology uses DNA microarrays to provide genetic information, aiding in the management of local epidemics and worldwide pandemics.
A computer-intensive mathematical model simulated mutation in flu genetic units, revealing a secondary, non-specific immune response that gives people temporary protection against nearly all variants. This understanding could inform the development of more effective vaccines offering longer-term immunity.
Researchers uncover molecular signal critical for selective recruitment of viral RNA segments to form complete flu genome. This discovery may help develop new vaccines and antiviral drugs targeting the genetic trick used by the flu virus.
A small genetic change in the PB2 gene makes influenza viruses more potent, warns of potential dangers of new strains. Research helps develop strategies for detecting future outbreaks and prepares for pandemics.
Researchers found that a minor change in the arrangement of molecules can turn a relatively benign flu virus into a deadly one. The study used mice to show that even a small amount of the virulent form of the virus was enough to cause fatal infections, highlighting the potential for animal-to-human transmission.
The nasal spray flu vaccine protected young children against the A/Sydney flu strain with an 86% efficacy rate, reducing disease severity and middle-ear infections. The two-year study showed overall protection of 92% and significant cross-protection against other strains.
A new study found that flu in children results in substantial use of outpatient medical resources, including 10 physician visits and over half resulting in antibiotic prescriptions. The study suggests that recommending an annual flu vaccine for all children could be a cost-effective national policy.
New data confirm Relenza's effectiveness in targeting viral replication and reducing complications in patients with influenza B. High concentrations of the drug in the lungs also reduce the risk of resistance development.
Researchers at UW-Madison have perfected a method for creating designer influenza viruses, which can be tailored to solve mysteries about flu strain mutations, spread, and illness. This technology may lead to more efficient influenza vaccines and safer gene therapies.
A new study found that women under 65 with certain chronic medical conditions experience substantial morbidity and mortality from acute cardiopulmonary events during influenza season. The study suggests that stronger efforts to reach younger high-risk patients are needed to improve influenza vaccination levels.
A study found that inhaled zanamivir significantly reduces the time to recover from influenza symptoms by up to one-third and complications by 71% in high-risk patients. It also showed faster return to normal activities and better health status scores compared to placebo.
Researchers at the University of Michigan have discovered a new anti-microbial agent called BCTP that effectively kills the influenza A virus in cell cultures and laboratory mice. The study found that BCTP is non-toxic to skin and mucous membranes, making it a promising alternative to traditional vaccines.
Researchers have identified an unusual molecular mechanism that amplifies the disease-causing power of influenza A virus, potentially explaining its lethality in past pandemics. The discovery may lead to better understanding of pathogenesis and identification of new markers for predicting pandemic potential.
Researchers at UW-Madison discovered a molecular mechanism that allows influenza viruses to cause sweeping damage throughout the body. The finding provides an additional marker for scientists to be aware of in their surveys of emerging viruses and may have broader implications in the virology field.
A new nasal spray vaccine, FluMist(TM), has shown promising results in preventing the flu and flu-related ear infections in children. The vaccine provided 93% protection against the flu and 98% protection against otitis media, a common complication of the flu.
University of Wisconsin-Madison experts conduct detailed surveillance on H5 influenza, a deadly strain found in birds that has infected eight people and killed three. The study aims to identify the source of the virus, test for genetic variation between bird and human strains, and determine potential public health risks.
A new influenza virus found in Hong Kong has spread directly from poultry to a boy, bypassing typical human adaptation. The virus, H5 subtype HK97, has not been shown to cause infections in humans before.
A new intranasal influenza vaccine has been shown to provide 93% protection against the flu in healthy young children. The vaccine was well-tolerated and safe for administration in a nasal spray format, offering an attractive alternative to traditional injection-based vaccines.